Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

Genitourinary cancers


Breaking news, expert video interviews, and educational materials for healthcare professionals managing genitourinary cancer patients.


Highlights

06-10-2023 | Prostate cancer | News

Add-on SBRT improves outcomes of men with oligometastatic CRPC

Patients with oligometastatic castration-resistant prostate cancer benefit from the addition of stereotactic body radiotherapy to first-line abiraterone acetate plus prednisone.

30-06-2023 | Prostate cancer | News

First-line talazoparib plus enzalutamide supported for mCRPC

Adding talazoparib to enzalutamide significantly improves the outcomes of untreated patients with metastatic castration-resistant prostate cancer, regardless of homologous recombination repair mutation status, shows the TALAPRO-2 trial.

31-05-2023 | Cardiotoxicity | News

Anthracyclines may increase heart failure risk among YA cancer survivors

Anthracycline exposure in young adults who previously received cancer treatment is associated with a significantly elevated risk for heart failure.
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

More on renal cell carcinoma

08-08-2023 | Renal cell carcinoma | News

Potential of pembrolizumab plus lenvatinib for non-clear-cell RCC shown

31-05-2023 | Cardiotoxicity | News

Anthracyclines may increase heart failure risk among YA cancer survivors

24-02-2023 | Renal cell carcinoma | News

CheckMate 914: Adjuvant nivolumab–ipilimumab not supported for high-risk RCC

20-01-2023 | Immunotherapy | News

IL-7 genetic variant linked to ICI toxicity

19-12-2022 | Immunotherapy | News

Obesity may increase irAE risk among nivolumab-treated patients

30-11-2022 | Renal cell carcinoma | News

Long-term findings support SABR for localized RCC
  • » This independent programme is supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany. All content has been developed independently by Springer Healthcare IME, in conjunction with an expert Faculty.

More on prostate cancer

20-10-2023 | Prostate cancer | News

Enzalutamide use supported for biochemically recurrent prostate cancer

06-10-2023 | Prostate cancer | News

Add-on SBRT improves outcomes of men with oligometastatic CRPC

30-06-2023 | Prostate cancer | News

First-line talazoparib plus enzalutamide supported for mCRPC

09-05-2023 | Prostate cancer | News

Prostate cancer in transgender women ‘not so rare’

More on bladder and urothelial cancer

20-04-2023 | Urothelial cancer | At a glance | Article

At a glance: Second and later line immunotherapy for advanced urothelial carcinoma

20-01-2023 | Immunotherapy | News

IL-7 genetic variant linked to ICI toxicity

16-01-2023 | Urothelial cancer | News

Neoadjuvant gemcitabine–cisplatin ‘a viable option’ for high-grade UTUC

19-12-2022 | Immunotherapy | News

Obesity may increase irAE risk among nivolumab-treated patients

23-11-2022 | Bladder cancer | News

MRE11 expression may serve as prognostic biomarker in nonmetastatic MIBC

30-09-2022 | ESMO 2022 | Conference coverage | News

High BMI tied to improved ICI outcomes in metastatic UC patients
Image Credits